textochbilcontainer
A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT
textochbilcontainer
OUR CLINICAL pipeline CONSISTS of late stage drug candidates with a combined peak sales potential estimated at USD 350–700
textochbilcontainer
Moberg pharma’s operations are fully financed, aiming at making MOB-015 the future market leader in nail fungus (onychomycosis).
Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus. On March 29, 2019, the company divested its OTC Business, see press release
32,90 kr
+2,5 %
- All pressreleases
- Regulatory
Subscribe
Calendar/presentations
Next calendar event: 2020-11-10 Interim report for July 2019 - September 2020Redemption of shares
On November 26, 2019, a payment of SEK 46.50 per share was made through redemption of shares.
Mycological cure rate after MOB-015 treatment, Phase 3 data
...
